Polyhemoglobin-Fibrinogen: A Novel Oxygen Carrier with Platelet-Like Properties in a Hemodiluted Setting
Polyhemoglobin (polyHb) is currently being assessed in phase III trials under various formulations. At present, none contain clotting factors or platelet substitutes to aid in hemostasis. We have prepared a novel blood substitute that is an oxygen carrier with platelet-like activity. This is formed...
Gespeichert in:
| Veröffentlicht in: | Artificial cells, blood substitutes, and immobilization biotechnology blood substitutes, and immobilization biotechnology, 2007-01, Vol.35 (5), p.481-489 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 489 |
|---|---|
| container_issue | 5 |
| container_start_page | 481 |
| container_title | Artificial cells, blood substitutes, and immobilization biotechnology |
| container_volume | 35 |
| creator | Wong, Naomi S. W. Chang, Thomas M. S. |
| description | Polyhemoglobin (polyHb) is currently being assessed in phase III trials under various formulations. At present, none contain clotting factors or platelet substitutes to aid in hemostasis. We have prepared a novel blood substitute that is an oxygen carrier with platelet-like activity. This is formed by crosslinking fibrinogen to hemoglobin to form polyhemoglobin-fibrinogen (polyHb-Fg). This was studied and compared to polyHb for its effect on coagulation both in vitro and in vivo. In the in vitro experiments, PolyHb-Fg showed similar clotting times as whole blood, whereas polyHb showed significantly higher clotting times. This result was confirmed in in vivo experiments using an exchange transfusion rat-model. Using PolyHb, exchange transfusion of 80% or more increased the normal clotting time (1-2 mins) to > 10 mins. Partial clots formed with PolyHb did not adhere to the tubing wall. With PolyHb-Fg, a normal clotting time is maintained, even with 98% exchange transfusion. |
| doi_str_mv | 10.1080/10731190701586210 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_17922313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68347233</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-c3fc375f88fefabfa353e06c47e5015c2996b7bf3201de4ff4e4b63acb25d1a03</originalsourceid><addsrcrecordid>eNqFkV1rFDEUhoNYbK3-AG8kV95Nzdd8qTdlsVZY7IJ6HTKZk53UTLImGdv990Z2QaRQr845nOd9OR8IvaLkgpKOvKWk5ZT2pCW07hpGyRN0RmvOKkE78bTkpV8VoD9Fz1O6JYRwQdkzdErbnjFO-RmaNsHtJ5jD1oXB-urKDtH6sAX_Dl_iL-EXOHxzvy81XqkYLUR8Z_OEN05lcJCrtf0BeBPDDmK2kLD1WOHrYjhat2QY8VfI2frtC3RilEvw8hjP0ferj99W19X65tPn1eW60qLtcqW50bytTdcZMGowitccSFOaUJctNev7ZmgHwxmhIwhjBIih4UoPrB6pIvwcvTn47mL4uUDKcrZJg3PKQ1iSbDouWsb5f0FGBBNt3xWQHkAdQ0oRjNxFO6u4l5TIP3-QD_5QNK-P5ssww_hXcTx8AT4cAOtNiLO6C9GNMqu9C9FE5bVNkj_m__4f-QTK5UmrCPI2LNGXCz8y3W8YX6j5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20424798</pqid></control><display><type>article</type><title>Polyhemoglobin-Fibrinogen: A Novel Oxygen Carrier with Platelet-Like Properties in a Hemodiluted Setting</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><creator>Wong, Naomi S. W. ; Chang, Thomas M. S.</creator><creatorcontrib>Wong, Naomi S. W. ; Chang, Thomas M. S.</creatorcontrib><description>Polyhemoglobin (polyHb) is currently being assessed in phase III trials under various formulations. At present, none contain clotting factors or platelet substitutes to aid in hemostasis. We have prepared a novel blood substitute that is an oxygen carrier with platelet-like activity. This is formed by crosslinking fibrinogen to hemoglobin to form polyhemoglobin-fibrinogen (polyHb-Fg). This was studied and compared to polyHb for its effect on coagulation both in vitro and in vivo. In the in vitro experiments, PolyHb-Fg showed similar clotting times as whole blood, whereas polyHb showed significantly higher clotting times. This result was confirmed in in vivo experiments using an exchange transfusion rat-model. Using PolyHb, exchange transfusion of 80% or more increased the normal clotting time (1-2 mins) to > 10 mins. Partial clots formed with PolyHb did not adhere to the tubing wall. With PolyHb-Fg, a normal clotting time is maintained, even with 98% exchange transfusion.</description><identifier>ISSN: 1073-1199</identifier><identifier>EISSN: 1532-4184</identifier><identifier>DOI: 10.1080/10731190701586210</identifier><identifier>PMID: 17922313</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Animals ; Blood Coagulation - physiology ; Blood substitutes ; Blood Substitutes - chemical synthesis ; Coagulation ; Erylthrocytes ; Exchange Transfusion, Whole Blood - methods ; Fibrinogen ; Fibrinogen - analogs & derivatives ; Fibrinogen - chemical synthesis ; Fibrinogen - chemistry ; Fibrinogen - pharmacology ; Hemodilution ; Hemodilution - adverse effects ; Hemoglobins - chemical synthesis ; Hemoglobins - chemistry ; Hemoglobins - pharmacology ; Hemorrhage ; Male ; Platelets ; Polyhemoglobin ; Rats ; Rats, Sprague-Dawley ; Whole Blood Coagulation Time</subject><ispartof>Artificial cells, blood substitutes, and immobilization biotechnology, 2007-01, Vol.35 (5), p.481-489</ispartof><rights>2007 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2007</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-c3fc375f88fefabfa353e06c47e5015c2996b7bf3201de4ff4e4b63acb25d1a03</citedby><cites>FETCH-LOGICAL-c478t-c3fc375f88fefabfa353e06c47e5015c2996b7bf3201de4ff4e4b63acb25d1a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/10731190701586210$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/10731190701586210$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,59646,60435,61220,61401</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17922313$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wong, Naomi S. W.</creatorcontrib><creatorcontrib>Chang, Thomas M. S.</creatorcontrib><title>Polyhemoglobin-Fibrinogen: A Novel Oxygen Carrier with Platelet-Like Properties in a Hemodiluted Setting</title><title>Artificial cells, blood substitutes, and immobilization biotechnology</title><addtitle>Artif Cells Blood Substit Immobil Biotechnol</addtitle><description>Polyhemoglobin (polyHb) is currently being assessed in phase III trials under various formulations. At present, none contain clotting factors or platelet substitutes to aid in hemostasis. We have prepared a novel blood substitute that is an oxygen carrier with platelet-like activity. This is formed by crosslinking fibrinogen to hemoglobin to form polyhemoglobin-fibrinogen (polyHb-Fg). This was studied and compared to polyHb for its effect on coagulation both in vitro and in vivo. In the in vitro experiments, PolyHb-Fg showed similar clotting times as whole blood, whereas polyHb showed significantly higher clotting times. This result was confirmed in in vivo experiments using an exchange transfusion rat-model. Using PolyHb, exchange transfusion of 80% or more increased the normal clotting time (1-2 mins) to > 10 mins. Partial clots formed with PolyHb did not adhere to the tubing wall. With PolyHb-Fg, a normal clotting time is maintained, even with 98% exchange transfusion.</description><subject>Animals</subject><subject>Blood Coagulation - physiology</subject><subject>Blood substitutes</subject><subject>Blood Substitutes - chemical synthesis</subject><subject>Coagulation</subject><subject>Erylthrocytes</subject><subject>Exchange Transfusion, Whole Blood - methods</subject><subject>Fibrinogen</subject><subject>Fibrinogen - analogs & derivatives</subject><subject>Fibrinogen - chemical synthesis</subject><subject>Fibrinogen - chemistry</subject><subject>Fibrinogen - pharmacology</subject><subject>Hemodilution</subject><subject>Hemodilution - adverse effects</subject><subject>Hemoglobins - chemical synthesis</subject><subject>Hemoglobins - chemistry</subject><subject>Hemoglobins - pharmacology</subject><subject>Hemorrhage</subject><subject>Male</subject><subject>Platelets</subject><subject>Polyhemoglobin</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Whole Blood Coagulation Time</subject><issn>1073-1199</issn><issn>1532-4184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV1rFDEUhoNYbK3-AG8kV95Nzdd8qTdlsVZY7IJ6HTKZk53UTLImGdv990Z2QaRQr845nOd9OR8IvaLkgpKOvKWk5ZT2pCW07hpGyRN0RmvOKkE78bTkpV8VoD9Fz1O6JYRwQdkzdErbnjFO-RmaNsHtJ5jD1oXB-urKDtH6sAX_Dl_iL-EXOHxzvy81XqkYLUR8Z_OEN05lcJCrtf0BeBPDDmK2kLD1WOHrYjhat2QY8VfI2frtC3RilEvw8hjP0ferj99W19X65tPn1eW60qLtcqW50bytTdcZMGowitccSFOaUJctNev7ZmgHwxmhIwhjBIih4UoPrB6pIvwcvTn47mL4uUDKcrZJg3PKQ1iSbDouWsb5f0FGBBNt3xWQHkAdQ0oRjNxFO6u4l5TIP3-QD_5QNK-P5ssww_hXcTx8AT4cAOtNiLO6C9GNMqu9C9FE5bVNkj_m__4f-QTK5UmrCPI2LNGXCz8y3W8YX6j5</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Wong, Naomi S. W.</creator><creator>Chang, Thomas M. S.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Polyhemoglobin-Fibrinogen: A Novel Oxygen Carrier with Platelet-Like Properties in a Hemodiluted Setting</title><author>Wong, Naomi S. W. ; Chang, Thomas M. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-c3fc375f88fefabfa353e06c47e5015c2996b7bf3201de4ff4e4b63acb25d1a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Blood Coagulation - physiology</topic><topic>Blood substitutes</topic><topic>Blood Substitutes - chemical synthesis</topic><topic>Coagulation</topic><topic>Erylthrocytes</topic><topic>Exchange Transfusion, Whole Blood - methods</topic><topic>Fibrinogen</topic><topic>Fibrinogen - analogs & derivatives</topic><topic>Fibrinogen - chemical synthesis</topic><topic>Fibrinogen - chemistry</topic><topic>Fibrinogen - pharmacology</topic><topic>Hemodilution</topic><topic>Hemodilution - adverse effects</topic><topic>Hemoglobins - chemical synthesis</topic><topic>Hemoglobins - chemistry</topic><topic>Hemoglobins - pharmacology</topic><topic>Hemorrhage</topic><topic>Male</topic><topic>Platelets</topic><topic>Polyhemoglobin</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Whole Blood Coagulation Time</topic><toplevel>online_resources</toplevel><creatorcontrib>Wong, Naomi S. W.</creatorcontrib><creatorcontrib>Chang, Thomas M. S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Artificial cells, blood substitutes, and immobilization biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, Naomi S. W.</au><au>Chang, Thomas M. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polyhemoglobin-Fibrinogen: A Novel Oxygen Carrier with Platelet-Like Properties in a Hemodiluted Setting</atitle><jtitle>Artificial cells, blood substitutes, and immobilization biotechnology</jtitle><addtitle>Artif Cells Blood Substit Immobil Biotechnol</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>35</volume><issue>5</issue><spage>481</spage><epage>489</epage><pages>481-489</pages><issn>1073-1199</issn><eissn>1532-4184</eissn><abstract>Polyhemoglobin (polyHb) is currently being assessed in phase III trials under various formulations. At present, none contain clotting factors or platelet substitutes to aid in hemostasis. We have prepared a novel blood substitute that is an oxygen carrier with platelet-like activity. This is formed by crosslinking fibrinogen to hemoglobin to form polyhemoglobin-fibrinogen (polyHb-Fg). This was studied and compared to polyHb for its effect on coagulation both in vitro and in vivo. In the in vitro experiments, PolyHb-Fg showed similar clotting times as whole blood, whereas polyHb showed significantly higher clotting times. This result was confirmed in in vivo experiments using an exchange transfusion rat-model. Using PolyHb, exchange transfusion of 80% or more increased the normal clotting time (1-2 mins) to > 10 mins. Partial clots formed with PolyHb did not adhere to the tubing wall. With PolyHb-Fg, a normal clotting time is maintained, even with 98% exchange transfusion.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>17922313</pmid><doi>10.1080/10731190701586210</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1073-1199 |
| ispartof | Artificial cells, blood substitutes, and immobilization biotechnology, 2007-01, Vol.35 (5), p.481-489 |
| issn | 1073-1199 1532-4184 |
| language | eng |
| recordid | cdi_pubmed_primary_17922313 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles) |
| subjects | Animals Blood Coagulation - physiology Blood substitutes Blood Substitutes - chemical synthesis Coagulation Erylthrocytes Exchange Transfusion, Whole Blood - methods Fibrinogen Fibrinogen - analogs & derivatives Fibrinogen - chemical synthesis Fibrinogen - chemistry Fibrinogen - pharmacology Hemodilution Hemodilution - adverse effects Hemoglobins - chemical synthesis Hemoglobins - chemistry Hemoglobins - pharmacology Hemorrhage Male Platelets Polyhemoglobin Rats Rats, Sprague-Dawley Whole Blood Coagulation Time |
| title | Polyhemoglobin-Fibrinogen: A Novel Oxygen Carrier with Platelet-Like Properties in a Hemodiluted Setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A51%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polyhemoglobin-Fibrinogen:%20A%20Novel%20Oxygen%20Carrier%20with%20Platelet-Like%20Properties%20in%20a%20Hemodiluted%20Setting&rft.jtitle=Artificial%20cells,%20blood%20substitutes,%20and%20immobilization%20biotechnology&rft.au=Wong,%20Naomi%20S.%20W.&rft.date=2007-01-01&rft.volume=35&rft.issue=5&rft.spage=481&rft.epage=489&rft.pages=481-489&rft.issn=1073-1199&rft.eissn=1532-4184&rft_id=info:doi/10.1080/10731190701586210&rft_dat=%3Cproquest_pubme%3E68347233%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20424798&rft_id=info:pmid/17922313&rfr_iscdi=true |